January 11-14, 2027 | San Francisco Marriott Marquis
January 15, 2027 | Virtual
January 11-14, 2027 | San Francisco
January 15, 2027 | Virtual
January 11-14, 2027 | San Francisco Marriott Marquis
January 15, 2027 | Virtual
2027 Participating Companies
Vivacelle Bio, Inc.
505(b)2-Ph3 clinical stage company focused on treating septic shock, multiple organ dysfunction syndrome, hemorrhagic shock & reperfusion injury by addressing conditions related to lack of blood supply including absolute hypovolemia & relative hypovolemia